Salute e Benessere
FYARRO Sets New Standard in Rare Oncology Market with Strong Growth Prospects | DelveInsight
FYARRO (albumin-bound) is a targeted therapy approved for the treatment of adults with locally advanced unresectable or metastatic malignant PEComa. This medication is specifically designed to combat cancer by targeting abnormal growth signals in perivascular epithelioid cells, which multiply uncontrollably in advanced PEComa. By blocking a key pathway involved in tumor growth, FYARRO helps slow or stop the spread of cancer. Unlike traditional chemotherapy, FYARRO functions as a precision therapy.
What sets FYARRO apart from other mTOR inhibitors is its use of nanoparticle technology, which enhances drug delivery directly into tumors. This allows for a more effective shutdown of the mTOR signaling pathways that drive cancer progression.
FYARRO became commercially available in the United States in February 2022 . As per the company's SEC filing for the quarter ending September 30, 2024 , net product sales reached for the three months and over the nine months. In comparison, during the same periods in 2023, sales were and , respectively. The year-over-year growth in both the quarterly and year-to-date figures for 2024 was mainly driven by robust market demand.
In addition to its role in treating PEComa, AADI Biosciences is also evaluating FYARRO in two Phase II clinical trials for advanced or recurrent endometrioid-type endometrial cancer (EEC) and neuroendocrine tumors (NETs). While new patient enrollment has been paused by the company, dosing continues for previously enrolled patients, with the studies set to provide initial efficacy signals in the coming months. The ongoing development of FYARRO underscores the company's commitment to improving treatment options for challenging cancers and advancing therapeutic options in unmet medical needs.
Learn more about FYARRO projected market size for PEComa @
Perivascular epithelioid cell neoplasms (PEComas) are rare tumors of the soft tissues, typically developing around small blood vessels in organs such as the lungs, gastrointestinal tract, kidneys, liver, and uterus. According to the WHO classification, PEComa not otherwise specified (NOS) encompasses both benign forms and more aggressive, malignant variants. One of the more serious presentations commonly encountered in clinical practice is abdominopelvic perivascular epithelioid cell sarcoma, often referred to as malignant PEComa. In 2023, the number of new PEComa cases in the United States was estimated at around 250, with projections indicating a gradual increase through 2034.
Wide surgical resection remains the standard approach for localized PEComa, although there are no established guidelines for systemic therapy in such cases. While there has been a notable instance of an 80% tumor reduction with cytotoxic chemotherapy using doxorubicin and ifosfamide in a patient with extremity PEComa, most cases have shown limited benefit. Reports often document either disease progression during chemotherapy or residual tumor presence post-surgery. Limited data exist regarding the use of neoadjuvant radiation alone, but it may be approached similarly to other localized high-grade sarcomas. As with many other soft tissue sarcoma (STS) subtypes, the role of adjuvant chemotherapy remains uncertain. Most patients treated with adjuvant anthracycline-based regimens have experienced recurrence within a median follow-up of less than two years.
Approximately 20% of patients are diagnosed with metastatic disease at presentation, and around 70% of those with initially localized malignant PEComa eventually develop metastases. Despite the disease's unpredictable progression, some patients—especially those with isolated or oligometastatic lesions or long disease-free intervals—may benefit from surgical removal of metastases, potentially achieving prolonged remission and control. Conventional STS chemotherapies have generally shown minimal activity in advanced PEComa, with agents such as anthracyclines, ifosfamide, paclitaxel, gemcitabine, and dacarbazine failing to produce significant responses.
Discover more about the PEComa market in detail @
Currently, there is no emerging drug in the pipeline targeting PEComa. However, the PEComa Market Dynamics might change in the coming years owing to quicker diagnosis and improved awareness of the disease. Pricing policies must also be considered to achieve great success in PEComa; this will further help launch an attractive product appropriate to the market.
To know more about the number of competing drugs in development, visit @
Discover how FYARRO is shaping the PEComa treatment landscape @
remains the primary treatment approach for localized PEComas. In advanced or metastatic settings, conventional chemotherapy and tyrosine kinase inhibitors have delivered modest results. However, —have emerged as a promising therapy. FYARRO, the only FDA-approved treatment for advanced malignant PEComas, utilizes to deliver targeted action against tumors with elevated mTOR pathway activity, often linked to TSC1 or TSC2 mutations. In the pivotal FYARRO demonstrated an overall response rate (ORR) of 39%, a median duration of response (mDOR) of 39.7 months, and a median overall survival of 53.1 months, earning its place as the preferred treatment in NCCN guidelines.
Although FYARRO is central to current treatment strategies, other mTOR inhibitors—such as
—have shown clinical benefit despite not being specifically approved for PEComa. For example, everolimus has achieved sustained disease control in cases of metastatic small bowel PEComa. Additionally, the VEGFR inhibitor has been used
to reduce tumor vascularization, though its effectiveness is still under evaluation. Traditional sarcoma chemotherapies have generally shown
in PEComa, underscoring FYARRO's unique role.
Nevertheless, several unmet needs persist, including the , to develop for advanced disease, and to identify reliable prognostic biomarkers for tailoring therapy. into innovative targeted therapies could be key to overcoming these challenges.
Dive deeper to get more insight into FYARRO's strengths & weaknesses relative to competitors @
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PEComa companies, including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PEComa companies, including among others.
report delivers an in-depth understanding of market trends, market drivers, market barriers, and key STS companies such as among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key STS companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/fyarro-sets-new-standard-in-rare-oncology-market-with-strong-growth-prospects--delveinsight-302431215.html